Investigating the effect of Empagliflozin on spirometric indices

Investigating the effect of Empagliflozin on spirometric indices in COPD patients with Type 2 Diabetes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191209045671N4

Enrollment

Registered

2025-09-10

Start date

2024-12-07

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Copd.

Interventions

Intervention group: diabetes control treatment with empagliflozin drug for 5 months.

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: All Copd patients with type 2 referred to the endocrinology clinic of Kausar Semnan Hospital who do not use SGLT2 drugs for their control.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FEV1 (Forced Expiratory Volume in First Second). Timepoint: Befor and after the study. Method of measurement: Spirometry.;PEF Maximum airflow or velocity during forced exhalation that begins with a full exhalation. Timepoint: Befor and after the study. Method of measurement: Spirometry.;FEV1/FVC A fraction of the vital capacity that can be removed from the lungs in the first second during exhalation. Timepoint: Befor and after the study. Method of measurement: Spirometry.;MMEF Average expiratory airflow velocity in the middle half of the strong exhalation maneuver. Timepoint: Befor and after the study. Method of measurement: Spirometry.	—

Measure

Time frame

FEV1 (Forced Expiratory Volume in First Second). Timepoint: Befor and after the study. Method of measurement: Spirometry.;PEF Maximum airflow or velocity during forced exhalation that begins with a full exhalation. Timepoint: Befor and after the study. Method of measurement: Spirometry.;FEV1/FVC A fraction of the vital capacity that can be removed from the lungs in the first second during exhalation. Timepoint: Befor and after the study. Method of measurement: Spirometry.;MMEF Average expiratory airflow velocity in the middle half of the strong exhalation maneuver. Timepoint: Befor and after the study. Method of measurement: Spirometry.

—

Secondary

Measure	Time frame
ESR. Timepoint: Before and after the study. Method of measurement: Laboratory methods.;CRP. Timepoint: Befor and after the study. Method of measurement: Laboratory methods.;6-minute exercise test. Timepoint: Befor and after the study. Method of measurement: 6-minute exercise test.;Oxygen saturation drop in 6-minute exercise. Timepoint: Befor and after the study. Method of measurement: Pulse oximeter.;Score in CAT questionnaire. Timepoint: Befor and after the study. Method of measurement: CAT questionnaire.	—

Measure

Time frame

ESR. Timepoint: Before and after the study. Method of measurement: Laboratory methods.;CRP. Timepoint: Befor and after the study. Method of measurement: Laboratory methods.;6-minute exercise test. Timepoint: Befor and after the study. Method of measurement: 6-minute exercise test.;Oxygen saturation drop in 6-minute exercise. Timepoint: Befor and after the study. Method of measurement: Pulse oximeter.;Score in CAT questionnaire. Timepoint: Befor and after the study. Method of measurement: CAT questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoumebitaraf

Semnan University of Medical Sciences

Masoumebitaraf@yahoo.com+98 23 4170 3365

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026